The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies

References

• Galassi FM, Borghi C. A brief history of uric acid: from gout to cardiovascular risk factor. Eur J Intern Med 2015;26:373
   PubMed Web of Science ®Google Scholar
• Li M, Hu X, Fan Y, et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. Sci Rep 2016;6:19520
   PubMed Web of Science ®Google Scholar
• Braga F, Pasqualetti S, Ferraro S, et al. Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: a systematic review and meta-analysis. Clin Chem Lab Med 2016;54:7-15
   PubMed Web of Science ®Google Scholar
• Borghi C, Desideri G. Urate-lowering drugs and prevention of cardiovascular disease: the emerging role of xanthine oxidase inhibition. Hypertension 2016;67:496-8
   PubMed Web of Science ®Google Scholar
• Chen C, Lu JM, Yao Q. Hyperuricemia-related diseases and xanthine oxidoreductase (XOR) inhibitors: an overview. Med Sci Monit 2016;22:2501-12
   PubMed Web of Science ®Google Scholar
• Borghi C, Rosei EA, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens 2015;33:1729-41
   PubMed Web of Science ®Google Scholar
• Katsiki N, Karagiannis A, Athyros VG, et al. Hyperuricaemia: more than just a cause of gout? J Cardiovasc Med 2013;14:397-402
   Google Scholar
• Zalawadiya SK, Veeranna V, Mallikethi-Reddy S, et al. Uric acid and cardiovascular disease risk reclassification: findings from NHANES III. Eur J Prev Cardiol 2015;22:513-18
   PubMed Web of Science ®Google Scholar
• Storhaug HM, Norvik JV, Toft I, et al. Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from The Tromsø Study. BMC Cardiovasc Disord 2013;13:115
   PubMed Web of Science ®Google Scholar
• Yuan H, Yu C, Li X, et al. Serum uric acid levels and risk of metabolic syndrome: a dose-response meta-snalysis of prospective studies. J Clin Endocrinol Metab 2015;100:4198-207
   PubMed Web of Science ®Google Scholar
• Shih MH, Lazo M, Liu SH, et al. Association between serum uric acid and nonalcoholic fatty liver disease in the US population. J Formos Med Assoc 2015;114:314-20
   PubMed Web of Science ®Google Scholar
• Kanbay M, Jensen T, Solak Y, et al. Uric acid in metabolic syndrome: from an innocent bystander to a central player. Eur J Intern Med 2016;29:3-8
   PubMed Web of Science ®Google Scholar
• De Cosmo S, Viazzi F, Pacilli A, et al.; AMD-Annals Study Group. Serum uric acid and risk of CKD in type 2 diabetes. Clin J Am Soc Nephrol 2015;10:1921-9
   PubMed Web of Science ®Google Scholar
• Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004;44:642-50
   PubMed Web of Science ®Google Scholar
• Chonchol M, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007;50:239-47
   PubMed Web of Science ®Google Scholar
• Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006;47:51-9
   PubMed Web of Science ®Google Scholar
• Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010;5:1388-93
   PubMed Web of Science ®Google Scholar
• Whelton A, Macdonald PA, Zhao L, et al. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol 2011;17:7-13
   PubMed Web of Science ®Google Scholar
• Mackenzie IS, Ford I, Walker A, et al., on behalf of the ALL-HEART study group. A multi-centre, prospective, randomised, open-label, blinded endpoint trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALLHEART study. BMJ Open 2016;6:e013774
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41:1183-90
   PubMed Web of Science ®Google Scholar
• Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38:1101-6
   PubMed Web of Science ®Google Scholar
• Luk AJ, Levin GP, Moore EE, et al. Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford) 2009;48:804-6
   PubMed Web of Science ®Google Scholar
• Dubreuil M, Zhu Y, Zhang Y, et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis 2014;74:1368-7
   PubMed Web of Science ®Google Scholar
• Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008;300:924-32
   PubMed Web of Science ®Google Scholar
• Chen JH, Lan JL, Cheng CF. Effect of Urate-lowering therapy on all-cause and cardiovascular mortality in hyperuricemic patients without gout: a case-matched cohort study. PLoS One 2015;10:e0145193
   PubMed Web of Science ®Google Scholar
• White W, Chohan S, Dabholkar A, et al. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. Am Heart J 2012;164:14-20
   PubMed Web of Science ®Google Scholar
• MacDonald TM, Ford I, Nuki G, et al. Protocol of the febuxostat versus allopurinol streamlined trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open 2014;4:e005354
   PubMed Web of Science ®Google Scholar
• Hosoya T, Kimura K, Itoh S, et al. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. Trials 2014;15:26
   PubMed Web of Science ®Google Scholar